GlassScriptPhysician profile
Lawrence J Langan
NPI 1053391482
$8,966.18
in general payments reported to CMS, 2019-2025
35 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $725 · 2021: $1,680 · 2022: $1,313 · 2023: $1,489 · 2024: $1,305 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,770.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $934.93 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $656.37 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $585.79 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $583.06 | 2021-2024 | Zeposia |
| Pfizer INC. | $415.45 | 2019-2025 | |
| Gilead Sciences, INC. | $404.65 | 2019-2024 | Livdelzi |
| Ardelyx, INC. | $372.51 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $242.52 | 2019-2021 | |
| Lilly USA, LLC | $228.74 | 2023-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $222.16 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $219.36 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Madrigal Pharmaceuticals | $217.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $208.41 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $201.19 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $180.05 | 2022-2025 | |
| Evoke Pharma, INC. | $118.77 | 2021-2025 | Gimoti |
| Shionogi INC | $100.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $96.45 | 2022-2024 | Dupixent |
| Concordia Pharmaceuticals INC. | $90.37 | 2019 | |
| Braintree Laboratories, INC. | $85.69 | 2019-2023 | Sutab |
| Ferring Pharmaceuticals INC. | $82.43 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $76.19 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $70.83 | 2021 | |
| Aimmune Therapeutics, INC. | $62.80 | 2024-2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $61.76 | 2025 | Iqirvo |
| Qol Medical, LLC | $55.00 | 2021 | |
| Intra-Sana Laboratories | $33.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.26 | 2023 | Cyltezo |
| Vibrant Gastro, INC. | $25.67 | 2024 | Vibrant Starter Kit |
| Vivus LLC | $23.71 | 2024 | Pancreaze |
| Organon LLC | $23.03 | 2023 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $18.06 | 2023 | |
| Alfasigma USA, INC. | $14.60 | 2021 | |
| Endo Pharmaceuticals INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Langan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.